SCHEMBL23134841

SCHEMBL23134841

C=Cc1c(C)nn(CC)c1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.40
LMNA P02545 5/20 0.40
HTT P42858 2/20 0.40
MAPT P10636 7/20 0.40
ADORA2A P29274 2/20 0.39
ADORA2B P29275 2/20 0.39
RAB9A P51151 5/20 0.39
NPC1 O15118 3/20 0.39
ATM Q13315 1/20 0.38
ALOX15 P16050 1/20 0.36
KDM4E B2RXH2 2/20 0.34
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
HPGD P15428 2/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ALDH1A1 P00352 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3322655 0.81 SMN1; SMN2 (0.42) SMN1; SMN2LMNAHTTMAPTADORA2A
SCHEMBL21766426 0.75 NPC1 (0.43) SMN1; SMN2LMNAMAPTADORA2AADORA2B
SCHEMBL22412126 0.75 SMN1; SMN2 (0.38) SMN1; SMN2LMNAHTTMAPTADORA2A
SCHEMBL22412127 0.75 SMN1; SMN2 (0.38) SMN1; SMN2LMNAHTTMAPTADORA2A
SCHEMBL15824550 0.73 ALDH1A1 (0.50) SMN1; SMN2LMNAHTTMAPTADORA2A
SCHEMBL8649530 0.72 ALDH1A1 (0.54) SMN1; SMN2LMNAHTTMAPTADORA2A
SCHEMBL19912162 0.71
SCHEMBL23134903 0.69 ADORA2A (0.42) ADORA2AADORA2B
SCHEMBL13682869 0.69 GLS (0.35) KDM4EALDH1A1
SCHEMBL22538635 0.68 ADORA2A (0.42) SMN1; SMN2LMNAHTTMAPTADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021055326-A1 AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 WO disclosed